Affordable Access

deepdyve-link
Publisher Website

Efficacy of topical dorzolamide 2% in diabetic cystoid macular edema

Authors
  • Badawi, Amani E
  • Mokbel, Tharwat H.
  • Elhefney, Eman M
  • Hagras, Sherein M.
  • Abdelhameed, Ameera G
Type
Published Article
Journal
International Journal of Ophthalmology
Publisher
Press of International Journal of Ophthalmology (IJO Press)
Publication Date
Sep 18, 2021
Volume
14
Issue
9
Pages
1413–1418
Identifiers
DOI: 10.18240/ijo.2021.09.18
PMID: 34540619
PMCID: PMC8403856
Source
PubMed Central
Keywords
Disciplines
  • Clinical Research
License
Unknown

Abstract

AIM To study the effect of topical dorzolamide 2% on macular thickness reduction in diabetic cystoid macular edema (CME). METHODS This was a prospective, non-randomized, open study including eyes with diabetic macular edema (DME). All eyes received topical dorzolamide 2% three times daily for one month. Changes in best-corrected visual acuity (BCVA), and central macular thickness (CMT) by optical coherence tomography) were evaluated at 1wk, 1, and 3mo post-treatment. RESULTS Ninety-three eyes (84 patients) were included. Mean±SD (logMAR) BCVA improved significantly from 1.08±0.26 pretreatment to 0.66±0.24 at 1mo and 0.87±0.26 at 3mo post-treatment ( P <0.001 both). The mean±SD CMT was significantly reduced from 535.27±97.4 µm at baseline to 357.43±125.8 µm at 1mo and 376.23±114.5 µm at 3mo post-treatment ( P <0.001 both). No significant ocular or systemic side effects were recorded. CONCLUSION Topical dorzolamide 2% results in significant improvement of mean BCVA and reduction of mean CMT at 3mo post-treatment. It can be used as an effective, affordable, and safe therapy for treatment of non-refractory diabetic CME.

Report this publication

Statistics

Seen <100 times